Biotech Startups
9,890 companies tagged Biotech, with their investors and founders.
RNAV8 Bio develops a toolkit for engineering mRNA therapeutics, optimizing non-coding sequences to improve expression and efficacy of mRNA-based treatments. The company serves pharmaceutical and biotech organizations seeking to expand the clinical application of mRNA technology.
3 investors
Rocket Pharmaceuticals develops gene therapies to treat patients with rare genetic diseases, focusing on cardiovascular and hematologic disorders. The company creates potentially curative treatments at the genetic level for inherited and rare diseases.
3 investors
Route 92 Medical develops neurointervention catheter systems and devices aimed at improving outcomes for neurovascular patients, including stroke treatment. Its products are designed to navigate tortuous vascular anatomy and reach target locations for procedures such as aspiration.
3 investors
Rx Redefined provides a platform and management services for DMEPOS (durable medical equipment, prosthetics, orthotics, and supplies) ordering, handling revenue cycle processes, compliance checks, and audit processing for physicians. It integrates with existing EMR systems and reviews billing requirements, patient eligibility, and regulatory adherence for each physician order.
3 investors
Sable Bio develops AI-powered tools for researchers to evaluate drug safety and accelerate the development of safe and effective medicines. The company combines engineering with biological expertise to support pharmaceutical researchers in making better decisions.
3 investors
SAGA Diagnostics develops molecular residual disease testing for cancer detection, combining genomic expertise to identify cancer at early treatable stages. The company serves oncology and treatment decision-making in the healthcare sector.
3 investors
Santa Ana Bio develops engineered antibodies targeting immune system pathways to treat autoimmune and inflammatory diseases. The company uses precision therapeutics designed to either suppress overactive immune responses or reactivate dormant ones.
3 investors
Scenic Biotech develops modifier therapy, a genetic medicine approach that targets secondary functions in the genome to neutralize the impact of disease-causing mutations. The company uses its proprietary Cell-seq platform to develop small molecule programs for genetic disorders.
3 investors
Scentian Bio combines synthetic biology and AI to develop biosensors based on synthesized insect odorant receptors, creating a digital sense of smell and taste that can detect and measure the concentration of thousands of compounds. Spun out of Plant & Food Research, the company holds patents around its odorant-receptor biosensing technology.
3 investors
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases. The company uses a selective protein targeting approach designed to inhibit disease mechanisms rather than manage their downstream effects.
3 investors
Science37 operates a decentralized clinical trial platform supported by a network of medical directors across specialties including cardiology, neurology, psychiatry, pediatrics, and internal medicine. The company serves the clinical research and pharmaceutical industry.
3 investors
SciRhom is a biotech company developing first-in-class humanized antibodies against iRhom2, which regulates the enzyme TACE/ADAM17 to block pro-inflammatory signaling pathways. Its pipeline targets autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, and lupus nephritis.
3 investors
Seer develops proteomics tools for large-scale protein analysis, including an assay, automation instrument, and analysis software for studying the proteome across human and non-human samples. Its products serve researchers running deep, reproducible proteomic studies at scale.
3 investors
Senseye provides a predictive maintenance platform that uses industrial AI and domain knowledge to help maintenance teams assess asset health, anticipate failure risk, and prioritize actions across sites. It serves industrial and manufacturing organizations looking to scale predictive maintenance without relying on manual analysis or specialist skills.
3 investors
Sequence Bio discovers genetic causes of disease within Newfoundland and Labrador's founder population to develop breakthrough treatments, diagnostics, and preventions. The company focuses on translational biology and genetics research for patients globally.
3 investors
Sequencing.com offers free storage of personal DNA data along with tools and reports that turn genetic testing results into health-related insights for consumers. The company addresses data storage, usability, and privacy challenges created by widely available consumer genetic testing.
3 investors
3 investors
Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome. The company pioneered the development and FDA approval of VOWST, an oral live biotherapeutic.
3 investors
Serinus Biosciences uses AI and systems biology to design drug combinations that overcome cancer cells' resistance to existing treatments, targeting safer and more effective therapeutic options.
3 investors
Sesh+ manufactures nicotine pouches as a smoke-free alternative product for adult consumers seeking discrete, flavored nicotine delivery options.
3 investors
ShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.
3 investors
Shattuck Labs is a biopharmaceutical company developing a DR3 blocking antibody for the treatment of Inflammatory Bowel Disease and other inflammatory and immune-mediated diseases. Its lead candidate targets the DR3 immune receptor to block TL1A engagement on inflammation-driving immune cells.
3 investors
Sift Biosciences develops T-cell immunotherapies for cancer and autoimmune diseases, using an AI-driven discovery platform combined with metagenomics and high-throughput cellular screening to identify microbially derived molecules that activate memory T cells. Its SIFT platform supports pipelines in oncology and autoimmunity, with the latter partnered with a large pharmaceutical company.
3 investors
Sight develops immune signatures by analyzing live immune cells using AI to generate clinical insights. The company applies proprietary data and machine learning to immune cell analysis for diagnostic and clinical applications.
3 investors